Literature DB >> 22391528

In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.

Franco Borsini1, William Crumb, Silvia Pace, David Ubben, Barb Wible, Gan-Xin Yan, Christian Funck-Brentano.   

Abstract

The in vitro cardiac properties of dihydroartemisinin (DHA) plus piperaquine phosphate (PQP) were compared with those of other antimalarial compounds. Results with antimalarial drugs, chosen on the basis of their free therapeutic maximum concentration in plasma (C(max)), were expressed as the fold of that particular effect with respect to their C(max). The following tests were used at 37 °C: hERG (human ether-à-go-go-related gene) blockade and trafficking, rabbit heart ventricular preparations, and sodium and slow potassium ion current interference (I(Na) and I(Ks), respectively). Chloroquine, halofantrine, mefloquine, and lumefantrine were tested in the hERG studies, but only chloroquine, dofetilide, lumefantrine, and the combination of artemether-lumefantrine were used in the rabbit heart ventricular preparations, hERG trafficking studies, and I(Na) and I(Ks) analyses. A proper reference was used in each test. In hERG studies, the high 50% inhibitory concentration (IC(50)) of halofantrine, which was lower than its C(max), was confirmed. All the other compounds blocked hERG, with IC(50)s ranging from 3- to 30-fold their C(max)s. In hERG trafficking studies, the facilitative effects of chloroquine at about 30-fold its C(max) were confirmed and DHA blocked it at a concentration about 300-fold its C(max). In rabbit heart ventricular preparations, dofetilide, used as a positive control, revealed a high risk of torsades de pointes, whereas chloroquine showed a medium risk. Neither DHA-PQP nor artemether-lumefantrine displayed an in vitro signal for a significant proarrhythmic risk. Only chloroquine blocked the I(Na) ion current and did so at about 30-fold its C(max). No effect on I(Ks) was detected. In conclusion, despite significant hERG blockade, DHA-PQP and artemether-lumefantrine do not appear to induce potential torsadogenic effects in vitro, affect hERG trafficking, or block sodium and slow potassium ion currents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391528      PMCID: PMC3370756          DOI: 10.1128/AAC.05688-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

Review 1.  Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.

Authors:  Ajay Joshi; Tara Dimino; Yogesh Vohra; Changcong Cui; Gan-Xin Yan
Journal:  J Electrocardiol       Date:  2004       Impact factor: 1.438

Review 2.  Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation.

Authors:  Dongqi Wang; Chinmay Patel; Changcong Cui; Gan-Xin Yan
Journal:  Pharmacol Ther       Date:  2008-03-15       Impact factor: 12.310

3.  Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria.

Authors:  Mey Bouth Denis; Timothy M E Davis; Sean Hewitt; Sandra Incardona; Khim Nimol; Thierry Fandeur; Yi Poravuth; Chiv Lim; Doung Socheat
Journal:  Clin Infect Dis       Date:  2002-12-02       Impact factor: 9.079

4.  [Syncope through multifocal ventricular tachycardia during treatment with chloroquine. Study of the hisian electrogram and treatment by verapamil].

Authors:  J P Fauchier; J Lanfranchi; G Ginies; R Raynaud
Journal:  Ann Cardiol Angeiol (Paris)       Date:  1974 Jul-Sep

5.  The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.

Authors:  H L Greene; D M Roden; R J Katz; R L Woosley; D M Salerno; R W Henthorn
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

6.  Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes.

Authors:  J A Sánchez-Chapula; E Salinas-Stefanon; J Torres-Jácome; D E Benavides-Haro; R A Navarro-Polanco
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

7.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

Review 8.  Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.

Authors:  Y G Yap; A J Camm
Journal:  Am J Cardiol       Date:  1999-11-04       Impact factor: 2.778

9.  Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria.

Authors:  Oliver T Mytton; Elizabeth A Ashley; Leon Peto; Ric N Price; Yar La; Rae Hae; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Am J Trop Med Hyg       Date:  2007-09       Impact factor: 2.345

Review 10.  Cardiotoxicity of antimalarial drugs.

Authors:  Nicholas J White
Journal:  Lancet Infect Dis       Date:  2007-08       Impact factor: 25.071

View more
  25 in total

1.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.

Authors:  B R Moore; J M Benjamin; S Salman; S Griffin; E Ginny; M Page-Sharp; L J Robinson; P Siba; K T Batty; I Mueller; T M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 3.  Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

4.  Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine.

Authors:  Pere Millat-Martínez; Sam Salman; Oriol Mitjà; Quique Bassat; Brioni R Moore; Bàrbara Baro; Madhu Page-Sharp; Kevin T Batty; Leanne J Robinson; William Pomat; Harin Karunajeewa; Moses Laman; Laurens Manning
Journal:  Antimicrob Agents Chemother       Date:  2022-07-06       Impact factor: 5.938

5.  Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.

Authors:  Emma Hughes; Erika Wallender; Richard Kajubi; Prasanna Jagannathan; Teddy Ochieng; Abel Kakuru; Moses R Kamya; Tamara D Clark; Philip J Rosenthal; Grant Dorsey; Francesca Aweeka; Radojka M Savic
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

6.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.

Authors:  Brioni R Moore; John M Benjamin; Siu On Auyeung; Sam Salman; Gumul Yadi; Suzanne Griffin; Madhu Page-Sharp; Kevin T Batty; Peter M Siba; Ivo Mueller; Stephen J Rogerson; Timothy Me Davis
Journal:  Br J Clin Pharmacol       Date:  2016-03-27       Impact factor: 4.335

8.  Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries.

Authors:  Nicolas Vignier; Olivier Bouchaud; Andrea Angheben; Emmanuel Bottieau; Guido Calleri; Joaquín Salas-Coronas; Charlotte Martin; José Manuel Ramos; Matthieu Mechain; Christophe Rapp; Hans-Dieter Nothdurft; Maria Velasco; Azucena Bardají; Gerardo Rojo-Marcos; Leo G Visser; Christoph Hatz; Zeno Bisoffi; Tomas Jelinek; Stephan Duparc; Yann Bourhis; Silva Tommasini; Maurizio Iannucelli; Antonella Bacchieri; Giovan Giuseppe Mattera; Emilio Merlo Pich; Ronald H Behrens
Journal:  Malar J       Date:  2021-05-08       Impact factor: 2.979

9.  Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.

Authors:  Borje Darpo; Georg Ferber; Peter Siegl; Bart Laurijssens; Fiona Macintyre; Stephen Toovey; Stephan Duparc
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

10.  MMV in partnership: the Eurartesim® experience.

Authors:  David Ubben; Elizabeth M Poll
Journal:  Malar J       Date:  2013-06-19       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.